TENX

Business Context and Reporting Period

Company: Oxygen Biotherapeutics, Inc. (formerly Synthetic Blood International, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2008
Business Stage: Development stage biotechnology company focused on perfluorocarbon-based oxygen carriers (Oxycyte), lung treatment fluids (Fluorovent), and glucose biosensors. The company has no product revenue and relies entirely on external financing.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $3.2 million compared to the prior year quarter, driven by a significant rise in operating expenses and interest costs.
• Operating Expenses: Total operating expenses surged from $364,978 to $3,126,869.
  • General & Administrative (G&A): Increased from $213,486 to $2,818,581. This was primarily due to $2.17 million in consulting fees (mostly non-cash warrant issuances) and increased compensation for executive leadership.
  • Research & Development (R&D): Increased from $151,492 to $308,288 due to resumed funding of Phase II clinical trials and increased laboratory supplies.
• Interest Expense: Increased by $499,537, largely due to the recognition of $319,135 in interest expense upon the conversion of debt to equity and amortization of debt discounts from recent financing.
• Liquidity: Cash balances increased significantly from $125,738 to $6.09 million, fueled by $2.15 million in net cash provided by financing activities (warrant exercises and convertible notes).

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. The company requires substantial additional funds to complete clinical trials and regulatory approvals. Management believes current working capital is sufficient for fiscal year 2009 but will need additional financing by the end of 2009.
• Product Development:
  • Oxycyte: Phase II trials are ongoing (severe brain injury and hip surgery). Phase II-B protocol is under FDA review. Phase III studies are expected to commence after Phase II results.
  • Fluorovent & Glucose Biosensor: Still in animal testing stages; human testing applications are not expected for at least one year.
• Unusual Items:
  • Warrant Exercise Error: The company identified a pricing error in warrant exercises totaling $140,000, which is now recorded as a current liability owed to investors.
  • Debt Conversion: Converted $339,756 of notes payable into 1.38 million shares of common stock, triggering significant non-cash interest expense.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of July 31, 2008, due to material weaknesses including incompatible duties in cash disbursements, lack of sufficient accounting personnel, and failure to maintain complete copies of significant contracts.
• Commitments: Entered into a license agreement with Virginia Commonwealth University involving future royalty payments (up to 25% of net sales) and milestone payments totaling up to $1.3 million per product upon regulatory approval.

Investor Verification Checklist

• Financing Runway: Verify if the company has secured the additional equity or debt financing required by the end of 2009 to avoid ceasing operations.
• Internal Control Remediation: Confirm the hiring of a permanent Chief Financial Officer and the implementation of the proposed corrective measures for internal controls.
• Warrant Liability: Monitor the resolution of the $140,000 liability arising from the warrant exercise pricing error.
• Clinical Trial Progress: Track the FDA review status of the Phase II-B protocol for severe brain injury and the revised Phase II protocol for sickle cell pain crisis.
• Dilution Risk: Assess the impact of the large number of outstanding warrants (121.3 million) and convertible notes on future share count and earnings per share.